Dicer­na and Boehringer part­ner on RNAi treat­ment for NASH

Phar­ma gi­ant Boehringer In­gel­heim In­ter­na­tion­al is part­ner­ing with Dicer­na Phar­ma­ceu­ti­cals $DR­NA on a re­search and li­cens­ing deal to ad­vance treat­ments for chron­ic liv­er dis­eases.

Dicer­na gets $10 mil­lion in an up­front pay­ment, and could re­ceive up to an ad­di­tion­al $191 mil­lion in po­ten­tial mile­stone pay­ments and R&D re­im­burse­ments.

The duo will ini­tial­ly fo­cus on non­al­co­holic steato­hep­ati­tis (NASH), al­so known as non­al­co­holic fat­ty liv­er dis­ease, which has been a bea­con for a slew of bio­phar­ma com­pa­nies out to con­quer a fast-grow­ing ail­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER